April 22, 2021
Business News

Onxeo to Present New Preclinical Data at AACR 2021

PARIS–()–Regulatory News:

Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO) (Paris:ALONX) (NASDAQ OMX:ALONX), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), today announced the presentation of preclinical data confirming the differentiated antitumoral properties of the drug candidates generated by platON™, its patent-protected platform of decoy-agonists of the DNA Damage Response, in e-poster sessions during the American Association for Cancer Research (AACR 2021) virtual annual meeting on April 10, 2021.

The first e-poster supports the ability of AsiDNA™, the…

Click here to view the original article.

Related Posts

You might also like ...

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Romeo Power Inc. f/k/a RMG Acquisition Corp. (RMO) on Behalf of Investors
Snap-on Announces First Quarter 2021 Results
Online Grocer Farmstead Taps WhatsApp, Facebook Leader Linda K. Lee to Lead Business Development and Grocery OS Partnerships